Drug Sensitivity Testing for Cancer Therapy, Key Areas.

Area of Science:

• Oncology
• Pharmacology
• Biomedical Science

Background:

• Cancer remains a leading cause of mortality worldwide, with effective drug selection being critical for patient survival in clinical trials.
• Drug Sensitivity Testing (DST) has been employed to guide anticancer drug selection, showing modest improvements in drug response rates over two decades.
• The underlying mechanisms and clinical applicability of DST require further investigation, particularly concerning the correlation between in vitro drug resistance and clinical outcomes across diverse tumor types.

Purpose of the Study:

• To review the advancements and future directions of Drug Sensitivity Testing (DST) in clinical oncology.
• To highlight the importance of understanding DST mechanisms for improved therapeutic prediction and drug selection.
• To emphasize the need for cost-effective, versatile, and automated DST platforms in clinical practice.

Main Methods:

• Review of current literature and clinical practices related to Drug Sensitivity Testing (DST).
• Analysis of the technical progress and limitations of existing DST platforms.
• Exploration of the relationship between in vitro drug resistance, tumor characteristics, and clinical treatment benefits.

Main Results:

• Drug Sensitivity Testing (DST) has shown incremental benefits in cancer drug selection, but its full potential is limited by a lack of understanding of underlying mechanisms.
• Current DST approaches require advancements towards miniaturization, versatility, and cost-effectiveness to be widely adopted.
• Future trends in DST involve multi-parameter analysis, automation, and integration of advanced biomedical knowledge for precise oncologic profiling.

Conclusions:

• Drug Sensitivity Testing (DST) holds significant promise for improving cancer patient outcomes through personalized drug selection.
• Further research into cancer biology, pharmacology, and omics-level analysis is essential for enhancing DST's predictive power.
• The development of non-invasive, versatile, and automated DST platforms could significantly impact global cancer survival rates.